H2020Индивидуална стипендия2021–2023

TARGETOF · Mass cytometry nanotools for intracellular target engagement. Towards precision medicine.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-08-31
Финансиране от ЕС: 160 932 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Нанотехнологии и масова цитометрия се използват за откриване на множество протеини, които лекарствата атакуват в раковите клетки. Това помага за по-добро разбиране на действието на терапията и избора на подходящо лечение за всеки пациент, за да се намалят страничните ефекти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Mass cytometry nanotools for intracellular target engagement. Towards precision medicine.

• What is the problem/issue being addressed? Cancer is the second highest cause of death in Europe, with 3.7 million estimated new cases and 1.9 million deaths each year. One of the main strategies in recent cancer therapy has been the development of drugs which target multiple cellular proteins at the same time. This strategy aims to block simultaneously different cancer pathways and thus it is expected to avoid the resistance to therapy. The drawback of this strategy is the appearance of side effects which may force a reduction in the dose. Then, it is clear that a better understanding of the targets of a drug is the key for a personalized cancer therapy, since most effective drugs with reduced side effects could be individually selected. This project tries to develop of novel methods based on nanotechnology to detect multiple targets in a single experiment and, in doing so, help fighting cancer. • Why is it important for society? The project has developed new tools to better understand cancer disease in a personalized manner, using the new technology of mass cytometry. These tools can contribute to patient´s health by improving diagnostics and prediction of disease outcomes, while informing medical doctors of the sensibility of each patient to a given treatment in a personalized manner. The technology can also help scientist understand the mode-of-action of drugs and why they produce side effects. Early understanding of the disease in a personalized manner means prevention, and prevention means a better management of disease, with more rapid and efficient treatment. • What are the overall objectives? The central aim of this research project is to develop a novel method based on nanotechnology and the new technique of mass cytometry to capture the targets of a drug for further analysis. The project objectives are: to synthesise nanoparticles detectable by mass cytometry, to develop a novel assay for mass cytometry analysis and to validate the assay by comparison with conventional methods.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cancer is the second highest cause of death in Europe and one of the biggest challenges facing humanity. The discovery of multi-kinase inhibitors has emerged as a strong alternative treatment for many cancers. However, the appearance of severe side effects due to their intrinsic target promiscuity limits the dosage and efficiency of these treatments. Therefore the characterisation of this promiscuity is crucial to develop selective and safe treatments. We propose a versatile and efficient approach to detect the binding of a given drug to target proteins. Combining intracellular target engagement devices based on nanotechnology with the state-of-the-art mass cytometry techniques, this approach will allow one-step target engagement profiling, and thus will streamline the discovery of the mode-of-action of a given drug. Furthermore, the development of an intracellular barcoding system in combination with the multiplexing capacities of mass cytometry will allow for the combination of multiple cell types in one single experiment, further accelerating the target deconvolution process. This research will greatly contribute to the development of a straightforward method to detect the most expressed targets in patient biopsies, and to select the best therapy for a given patient. This fellowship will consolidate me as an independent researcher, providing me with the opportunity for many cross-disciplinary collaborations, and to establish myself as an expert in the field of precision medicine.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSIDAD DE GRANADA · GranadaКоординаторИспания